A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children (M2-ABMG)
A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants
Sponsor: Bill and Melinda Gates Foundation
This PHASE4 trial investigates Adverse Event Following Immunisation and is currently completed. Bill and Melinda Gates Foundation leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE4
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Not Yet Recruiting → Completed
-
Jan 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bill and Melinda Gates Foundation
- Fidec Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.